Foghorn Therapeutics (FHTX) Interest Coverage Ratio (2019 - 2021)
Foghorn Therapeutics (FHTX) posted quarterly Interest Coverage Ratio of 0.35 for Q1 2026, up 95.72% year-over-year from 0.18 in Q1 2025, and up 97.5% quarter-over-quarter from 14.19 in Q4 2025.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Interest Coverage Ratio (2019 - 2021) Analysis & Trends
Foghorn Therapeutics' Interest Coverage Ratio history runs 8 years deep, the most recent figure standing at 0.35 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 95.72% year-over-year to 0.35; the TTM figure through Mar 2026 stood at 1.4 (up 92.81% YoY), while the FY2025 annual figure was 0.46, up 25.38% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 0.35, up from 14.19 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 3.1 in Q4 2024, with the low at 954.08 in Q3 2024.
- The 5-year median for Interest Coverage Ratio is 9.02 (2023), against an average of 77.92.
- Peak annual rise in Interest Coverage Ratio reached 1841.25% in 2024, while the deepest fall reached 10479.17% in 2024.
- Foghorn Therapeutics' Interest Coverage Ratio stood at 3.19 in 2022, then jumped by 94.42% to 0.18 in 2023, then surged by 1841.25% to 3.1 in 2024, then plunged by 557.58% to 14.19 in 2025, then jumped by 97.5% to 0.35 in 2026.
- Business Quant data shows FHTX's Interest Coverage Ratio at 0.35 in Q1 2026, 14.19 in Q4 2025, and 0.73 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | -21.24 |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 1.42 |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.08 |
| 10 | Foghorn Therapeutics | 347.14 Mn | 279.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -65.92 |
| Sep 30, 2021 | -52.63 |
| Jun 30, 2021 | -46.99 |
| Mar 31, 2021 | -47.59 |
| Dec 31, 2020 | -64.73 |
| Sep 30, 2020 | -91.53 |
| Jun 30, 2020 | -78.48 |
| Mar 31, 2020 | -53.19 |
| Dec 31, 2019 | -85.31 |
| Sep 30, 2019 | -115.93 |